|
1
|
Druker BJ: STI571 (Gleevec) as a paradigm
for cancer therapy. Trends Mol Med. 8(Suppl 4): S14–S18. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Melo JV, Hughes TP and Apperley JF:
Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program).
2003:132–152. 2003. View Article : Google Scholar
|
|
3
|
Baran Y, Salas A, Senkal CE, Gunduz U,
Bielawski J, Obeid LM and Ogretmen B: Alterations of
ceramide/sphingosine 1-phosphate rheostat involved in the
regulation of resistance to imatinib-induced apoptosis in K562
human chronic myeloid leukemia cells. J Biol Chem. 282:10922–10934.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cagnetta A, Garuti A, Marani C, et al:
Evaluating treatment response of chronic myeloid leukemia: Emerging
science and technology. Curr Cancer Drug Targets. 13:779–790. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ji J, Wang HS, Gao YY, Sang LM and Zhang
L: Synergistic antitumor effect of KLF4 and curcumin in human
gastric carcinoma cell line. Asian Pac J Cancer Prev. 15:7747–7752.
2014. View Article : Google Scholar
|
|
6
|
Süren D, Yıldırım M, Demirpençe Ö, Kaya V,
Alikanoğlu AS, Bülbüller N, Yıldız M and Sezer C: The role of high
mobility group box 1 (HMGB1) in colorectal cancer. Med Sci Monit.
20:530–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueda M, Takahashi Y, Shinden Y, Sakimura
S, Hirata H, Uchi R, Takano Y, Kurashige J, Iguchi T, Eguchi H, et
al: Prognostic significance of high mobility group box 1 (HMGB1)
expression in patients with colorectal cancer. Anticancer Res.
34:5357–5362. 2014.PubMed/NCBI
|
|
8
|
Sims GP, Rowe DC, Rietdijk ST, Herbst R
and Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev
Immunol. 28:367–388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu Y, Xie M, He YL, Xu WQ, Zhu S and Cao
LZ: Role of high mobility group box 1 in adriamycin-induced
apoptosis in leukemia K562 cells. Ai Zheng. 27:929–933. 2008.In
Chinese. PubMed/NCBI
|
|
11
|
Wild CA, Brandau S, Lotfi R, Mattheis S,
Gu X, Lang S and Bergmann C: HMGB1 is overexpressed in tumor cells
and promotes activity of regulatory T cells in patients with head
and neck cancer. Oral Oncol. 48:409–416. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Curtin JF, Liu N, Candolfi M, Xiong W,
Assi H, Yagiz K, Edwards MR, Michelsen KS, Kroeger KM, Liu C, et
al: HMGB1 mediates endogenous TLR2 activation and brain tumor
regression. PLoS Med. 6:e102009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang W, Tian J and Hao Q: HMGB1 combining
with tumor-associated macrophages enhanced lymphangiogenesis in
human epithelial ovarian cancer. Tumour Biol. 35:2175–2186. 2014.
View Article : Google Scholar
|
|
14
|
Zhao M, Yang M, Yang L, et al: HMGB1
regulates autophagy through increasing transcriptional activities
of JNK and ERK in human myeloid leukemia cells. BMB Rep.
44:601–606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura K, Yoshikawa N, Yamaguchi Y,
Kagota S, Shinozuka K and Kunitomo M: Antitumor effect of
cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma
cells involves adenosine A3 receptor stimulation. Anticancer Res.
26:43–47. 2006.PubMed/NCBI
|
|
16
|
Zhou X, Meyer CU, Schmidtke P and Zepp F:
Effect of cordycepin on interleukin-10 production of human
peripheral blood mononuclear cells. Eur J Pharmacol. 453:309–317.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koç Y, Urbano AG, Sweeney EB and McCaffrey
R: Induction of apoptosis by cordycepin in ADA-inhibited
TdT-positive leukemia cells. Leukemia. 10:1019–1024.
1996.PubMed/NCBI
|
|
18
|
Chen YH, Wang JY, Pan BS, Mu YF, Lai MS,
So EC, Wong TS and Huang BM: Cordycepin enhances cisplatin
apoptotic effect through caspase/MAPK pathways in human head and
neck tumor cells. Onco Targets Ther. 6:983–998. 2013.PubMed/NCBI
|
|
19
|
Jeong MH, Lee CM, Lee SW, Seo SY, Seo MJ,
Kang BW, Jeong YK, Choi YJ, Yang KM and Jo WS: Cordycepin-enriched
Cordyceps militaris induces immunomodulation and tumor growth delay
in mouse-derived breast cancer. Oncol Rep. 30:1996–2002.
2013.PubMed/NCBI
|
|
20
|
Zhang P, Huang C, Fu C, Tian Y, Hu Y, Wang
B, Strasner A, Song Y and Song E: Cordycepin (3′-deoxyadenosine)
suppressed HMGA2, Twist1 and ZEB1-dependent melanoma invasion and
metastasis by targeting miR-33b. Oncotarget. 6:9834–9853.
2015.PubMed/NCBI
|
|
21
|
Yao Z and Shulan Z: Inhibition effect of
Guizhi-Fuling-decoction on the invasion of human cervical cancer. J
Ethnopharmacol. 120:25–35. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar
|
|
23
|
Herold K, Moser B, Chen Y, et al: Receptor
for advanced glycation end products (RAGE) in a dash to the rescue:
Inflammatory signals gone awry in the primal response to stress. J
Leukoc Biol. 82:204–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Grösch S, Tegeder I, Niederberger E,
Bräutigam L and Geisslinger G: COX-2 independent induction of cell
cycle arrest and apoptosis in colon cancer cells by the selective
COX-2 inhibitor celecoxib. FASEB J. 15:2742–2744. 2001.PubMed/NCBI
|
|
25
|
Hirji I, Gupta S, Goren A, et al: Chronic
myeloid leukemia (CML): Association of treatment satisfaction,
negative medication experience and treatment restrictions with
health outcomes, from the patient's perspective. Health Qual Life
Outcomes. 11:1672013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jeong JW, Jin CY, Park C, et al: Induction
of apoptosis by cordycepin via reactive oxygen species generation
in human leukemia cells. Toxicol In Vitro. 25:817–824. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan XL, Chen L, Li MX, et al: Elevated
expression of Foxp3 in tumor-infiltrating Treg cells suppresses
T-cell proliferation and contributes to gastric cancer progression
in a COX-2-dependent manner. Clin Immunol. 134:277–288. 2010.
View Article : Google Scholar
|
|
28
|
Möbius C, Stein HJ, Spiess C, Becker I,
Feith M, Theisen J, Gais P, Jütting U and Siewert JR: COX2
expression, angiogenesis, proliferation and survival in Barrett's
cancer. Eur J Surg Oncol. 31:755–759. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sánchez-Fidalgo S, Martín-Lacave I,
Illanes M and Motilva V: Angiogenesis, cell proliferation and
apoptosis in gastric ulcer healing. Effect of a selective cox-2
inhibitor. Eur J Pharmacol. 505:187–194. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Okuma Y, Liu K, Wake H, et al: Anti-high
mobility group box-1 antibody therapy for traumatic brain injury.
Ann Neurol. 72:373–384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sessa L, Gatti E, Zeni F, et al: The
receptor for advanced glycation end-products (RAGE) is only present
in mammals and belongs to a family of cell adhesion molecules
(CAMs). PLoS One. 9:e869032014. View Article : Google Scholar
|
|
32
|
Ola MS, Nawaz M and Ahsan H: Role of Bcl-2
family proteins and caspases in the regulation of apoptosis. Mol
Cell Biochem. 351:41–58. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hoshyar R, Bathaie SZ and Sadeghizadeh M:
Crocin triggers the apoptosis through increasing the Bax/Bcl-2
ratio and caspase activation in human gastric adenocarcinoma, AGS,
cells. DNA Cell Biol. 32:50–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang L, Wang P, Wang H, et al: Fucoidan
derived from Undaria pinnatifida induces apoptosis in human
hepatocellular carcinoma SMMC-7721 cells via the ROS-mediated
mitochondrial pathway. Mar Drugs. 11:1961–1976. 2013. View Article : Google Scholar : PubMed/NCBI
|
